

PATENT SPECIFICATION

(11) 1 488 692

1 488 692

- (21) Application No. 42353/74 (22) Filed 30 Sept. 1974
 (31) Convention Application No. 402 657
 (32) Filed 1 Oct. 1973 in
 (33) United States of America (US)
 (44) Complete Specification published 12 Oct. 1977
 (51) INT CL³ C07D 471/04; A61K 31/395 (C07D 471/04, 221/00, 231/00)
 (52) Index at acceptance

C2C 1400 140X 1564 1626 213 214 215 220 22Y 246 247 250
 252 255 25Y 281 28X 29X 29Y 305 30Y 31Y 321 322
 323 32Y 332 337 339 342 34Y 351 352 355 35Y 360
 361 364 366 367 36Y 386 401 40Y 440 453 455 456
 45Y 470 601 610 611 616 617 620 621 623 624 628
 62X 630 634 635 640 650 652 660 665 668 670 671
 672 680 761 767 774 776 790 79Y KJ LE LH LP LS
 NF TU ZF


- (72) Inventors RONNIE RAY CRENSHAW, GEORGE MICHAEL LUKE and PAUL SIMINOFF

[3,4,b]
 (54) PYRAZOLO [3,4,6] QUINOLINES

(71) We, BRISTOL-MYERS COMPANY, a Corporation organised and existing under the laws of the State of Delaware, United States of America, having offices located at 345 Park Avenue, New York, New York 10022, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

The invention relates to certain substituted 1,3-dimethyl-1H-pyrazolo[3,4b]-quinolines and particularly to their use as antiviral agents in mammals. In another aspect, this invention relates to a method of preparing certain of such compounds.

U.S. Patent No. 3,600,393 to Graeve et al. and British Patent No. 1,355,205 describes compounds of the formula




and their pharmaceutically acceptable salts as having hypocholesterolemic and hypolipemic activity. The reaction scheme described therein is useful in preparing the general class of compounds utilized in the instant invention.

Stein et al, *J. Med. Chem.* 13 153 (1970) describes, *inter alia*, compounds which are 4-nitrogenously substituted-7-chloro-1,3-dimethyl-1H-pyrazolo[3,4b]-quinolines as having been tested for antimalarial activity.

U.S. Patent No. 3,234,142 to Wolfrum et al. describes compounds which are substituted 1-methyl-3-alkyl-1H-pyrazolo[3,4]quinolines, which however do not bear nitrogenous substituents in the 4-position. The reaction scheme described is essentially a reaction scheme which may be utilized to form intermediates used in the preparation of compounds of the instant invention.

It has now been found that the novel compounds corresponding to the following formula and pharmaceutically acceptable salts thereof, have antiviral activity in mammals:



SEE ERRATA SLIP ATTACHED

where E is hydrogen, lower alkoxy, lower alkylthio, hydroxyl, thio, trifluoromethyl, lower dialkylaminoalkoxy, amino, lower alkylamino, or lower dialkylamino,

where F is hydrogen, lower alkyl, lower alkoxy, hydroxyl, lower alkylthio, thio, trifluoromethyl, lower dialkylaminoalkoxy, amino, lower alkylamino, or lower dialkylamino,

where G is hydrogen, lower alkyl, lower alkoxy, lower alkylthio, hydroxyl, thio, trifluoromethyl, lower dialkylaminoalkoxy, amino, lower alkylamino, or lower dialkylamino,

where J is hydrogen, lower alkoxy, lower alkylthio, hydroxyl, thio, trifluoromethyl, lower dialkylaminoalkoxy, amino, lower alkylamino, or lower dialkylamino,

where n is an integer from 2 to 12,


where Y is amino, lower alkylamino, lower dialkylamino, or heteroamino wherein the heteroamino group is a 5 or 6 membered saturated substituted or unsubstituted ring;

and where at least one of E, F, G and J is other than hydrogen.

The pharmaceutically acceptable salts include the organic and inorganic acid addition salts, for example, those prepared from acids such as hydrochloric, sulfuric, sulfonic, tartaric, fumaric, hydrobromic, hydroiodic, glycolic, citric, maleic, phosphoric, succinic, or acetic. Such salts are prepared by conventional methods by reacting the free base with the desired acid. The compounds of this invention contain a multiplicity of salt forming groups and any or all of them can be combined with one or more acids to form acid salts.

The term "lower alkyl" as used herein means both straight and branched chain alkyl radicals containing 1 to 8 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, or butyl.

The preferred antiviral compounds of this invention correspond to the formula



where E is hydrogen or lower alkoxy,

where F is hydrogen, lower alkyl, lower alkoxy or lower alkylamino,

where G is hydrogen, lower alkyl, lower alkoxy or halogen,

where J is hydrogen or lower alkoxy,

where one or two of E, F, G and J are other than hydrogen,

where n is an integer from 2 to 6 inclusive, and where Y is dimethylamino, amino, diethylamino, dipropylamino, methylamino, ethylamino, propylamino, tertiary butylamino, or a heteroamino radical from the group




The compounds displaying antiviral activity, including novel compounds as described above are prepared by reacting the appropriately substituted 4-chloro-1,3-dimethyl-1H-pyrazolo[3,4b]quinoline with an amine of the formula




where n and Y are defined as above. This reaction is conveniently carried out in the presence of a nonreactive solvent and at elevated temperatures. Suitable solvents include aromatic solvents such as toluene or xylene, or polar solvents such as N,N-dimethylformamide or N,N-dimethylacetamide. Alternatively, an excess of the amine may be used to serve as a solvent. Preferably the reaction is carried out at from about 100°C. to about 200°C. Neither the temperature nor the solvent are critical. The resultant product is readily recoverable by conventional procedures, as for example, exemplified below.

The compounds described herein can generally be prepared according to a reaction scheme described in U.S. Patent No. 3,600,393 and exemplified below.


The reaction scheme is as follows:



While the above reaction scheme is generally employed to prepare the compounds described above, where B is an amino or substituted amino group the compounds can be prepared according to the following reaction scheme.



The amino group can then, if desired, be substituted by methods known in the art to yield the desired substituted amino group, e.g.,




An alternative route for the preparation of intermediate N-(3-methyl-pyrazolyl)anthranilic acids, is an Ullmann type reaction according to the following reaction scheme:

(11)

4

1,488,692

4



In the above reaction (XII), preferably M is an alkali metal. The catalyst is a copper containing catalyst, examples of which include copper powder, copper-bronze, cupric bromide, cupric oxide, cupric acetate, as well as other copper containing compounds. The reaction is preferably conducted in the presence of an inert solvent, with the application of heat sufficient to promote the reaction. Examples of suitable solvents include dimethyl formamide, n-amyl alcohol, xylene, diethylene glycol dimethyl ether and water.

The invention is further described in conjunction with the following examples, which are to be considered illustrative rather than limiting. Examples 1, 2, 5, 6 and 8 relate to the preparation of intermediates. All parts and percentages in the examples and throughout the specification are by weight unless otherwise specified. All temperatures are degrees Centigrade unless otherwise stated. In the following examples the formulas set forth are consistent with NMR (Nuclear Magnetic Resonance) and IR (infrared) analysis of the materials.

EXAMPLE 1.

2-Acetonil-7-methyl-4H-3,1-benzoxazin-4-one

A mixture of 4-methylantranilic acid (25.0 g., 0.17 mole) and diketene (13.95 g., 0.17 mole) in CCl_4 (250 ml.) was heated at reflux for 2.5 hours. Acetic anhydride (18.3 g., 0.18 mole) was added and the mixture was stirred under reflux for 16 hours. The mixture then was cooled and the product isolated by filtration; upon recrystallization there was obtained 2-acetonil-7-methyl-4H-3,1-benzoxazin-4-one (17.4 g., 48%), mp 142—144°C.

Analysis. Calculated for $\text{C}_{12}\text{H}_{11}\text{NO}_3$: C, 66.35; H, 5.10; N, 6.45. Found: C, 66.14; H, 5.23; N, 6.39.

EXAMPLE 2A.

N-(1,3-Dimethyl-5-pyrazolyl)-4-methylantranilic acid

The benzoxazinone of Example 1 (15.31 g., 0.071 mole) was added to a solution of methylhydrazine (3.90 g., 0.085 mole) in acetic acid (150 ml.) and the resultant solution was stirred at 80°C. for 2.5 hours. The solvent was removed and the product was recrystallized (acetonitrile) to yield N-(1,3-dimethyl-5-pyrazolyl)-4-methylantranilic acid (8.59 g., 49%), mp 188—192°C.

Analysis. Calculated for $\text{C}_{13}\text{H}_{15}\text{N}_3\text{O}_2$: C, 63.66; H, 6.16; N, 17.13. Found: C, 63.47; H, 6.20; N, 17.38.

EXAMPLE 2B.

N-(1,3-Dimethyl-5-pyrazolyl)-anthranilic acid

The catalyst employed was prepared by briefly digesting a commercial copper powder (1 micron) in 1 N aqueous hydrochloric acid. The powder was then filtered washed with water and acetone and oven dried.

To a solution of 4.84 grams of potassium carbonate in 18 ml. of water were added in succession 8.0 grams of o-iodobenzoic acid, 3.88 grams of 5-amino-1,3-dimethyl pyrazole and 0.8 gram of the copper catalyst. The mixture was stirred at reflux for 5 hours. There was then added an additional 50 milliliters of water, the mixture being refluxed in an additional 30 minutes and then filtered through diatomaceous earth. The filtrate was digested with decolorizing carbon, heated to reflux and filtered. The filtrate was cooled and acidified with 3N aqueous hydrochloric acid to produce N-(1,3-dimethyl-5-pyrazolyl)anthranilic acid, mp 175°—189°C., recrystallized from ethanol to give needles, mp 204—206°C.

EXAMPLE 3.

4 - (3 - Dimethylaminopropylamino) - 1,3,7 - trimethyl - 1H - pyrazolo[3,4b]-quinoline dihydrochloride

A mixture of N-(1,3-dimethyl-5-pyrazolyl)-4-methyl-antranilic acid (6.47 g., 0.026 mole) and phosphorus oxychloride (65 ml) was stirred at reflux for 3 hours. The cooled mixture was concentrated at 5 mm to a syrup which was poured onto ice. The mixture was basified with 4N NaOH and then was extracted with chloroform. The chloroform extracts were washed, dried and evaporated

to yield 4-chloro-1,3,7-trimethyl-1H-pyrazolo[3,4b]quinoline (4.75 g.). The product was treated with 3-dimethylaminopropylamine (50 ml.) and the mixture was stirred at reflux for 12 hours. The mixture was cooled and excess amine was evaporated at 5 mm. The residue was dissolved in chloroform and the resultant solution was washed in succession with aqueous potassium carbonate, water and brine. Drying (Na_2SO_4) and evaporation gave 6.86 g. Dissolution in 1-propanol and treatment with 2 equivalents of aqueous 1N hydrochloric acid yielded, after evaporation, 4-(3-dimethylaminopropylamino)-1,3,7-trimethyl-1H-pyrazolo[3,4b]quinoline dihydrochloride; recrystallization (aqueous ethanol) gave mp $290^\circ\text{--}293^\circ\text{C}$. (dec.).

Analysis Calculated for $\text{C}_{18}\text{H}_{22}\text{N}_4 \cdot 2\text{HCl}$: C, 56.25; H, 7.08; N, 18.22. Found: C, 56.45; H, 7.12; N, 18.24.

EXAMPLE 4.

1,3 - Dimethyl - 4 - (4 - dimethylaminobutylamino) - 1H - pyrazolo[3,4b]quinoline Dihydrochloride

A mixture of 4-chloro-1,3-dimethyl-1H-pyrazolo[3,4b]quinoline (4.63 g., 0.02 mole), potassium carbonate (2.76 g., 0.02 mole), and 4-dimethylaminobutylamine (2.23 g., 0.02 mole) in dimethylformamide (DMF) (60 ml.) was stirred at 130° for 16 hours. The solvent was removed at 5 mm and the residue was partitioned between water and chloroform. The organic phase was separated, washed with water, dried and evaporated to leave an oil (6.02 g., 97%). The dihydrochloride salt was prepared as described above; recrystallization (ethanol) yielded 1,3-dimethyl-4-(4-dimethylaminobutylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride mp 294°C . (dec.).

Analysis Calculated for $\text{C}_{18}\text{H}_{22}\text{N}_4 \cdot 2\text{HCl}$: C, 56.25; H, 7.08; N, 18.22. Found: C, 55.68; H, 6.88; N, 18.32.

EXAMPLE 5.

1,3 - Dimethyl - 4 - (3 - hydroxypropylamino) - 1H - pyrazolo[3,4b]quinoline hydrochloride

A mixture of 4-chloro-1,3-dimethyl-1H-pyrazolo[3,4b]quinoline (13.89 g., 0.06 mole), potassium carbonate (8.28 g., 0.06 mole), and 3-amino-1-propanol (4.95 g., 0.07 mole) in DMF (180 ml.) was stirred at 130° for 15 hours. Removal of the DMF and workup as described in Example 4 gave 11.92 g. (74%) of 1,3-dimethyl-4-(3-hydroxypropylamino)-1H-pyrazolo[3,4b]quinoline, mp $153.5\text{--}155^\circ\text{C}$. The hydrochloride salt was prepared as described above; mp $252.2\text{--}254.5^\circ\text{C}$.

Analysis Calculated for $\text{C}_{15}\text{H}_{18}\text{N}_4\text{O} \cdot \text{HCl}$: C, 58.75; H, 6.25; N, 18.27; Cl, 11.56. Found: C, 59.16; H, 6.26; N, 18.54; Cl, 11.59.

EXAMPLE 6.

1,3-Dimethyl-4-(3-chloropropylamino)-1H-pyrazolo[3,4b]quinoline hydrochloride

A solution of the hydroxy compound of Example 5 (11.50 g., 0.038 mole) and thionyl chloride (110 ml.) was heated at 60° for 2 hours. Evaporation yielded 4-(3-chloropropylamino)-1,3-dimethyl-1H-pyrazolo[3,4b]quinoline hydrochloride; mp $210\text{--}214^\circ$ after recrystallization (absolute ethanol).

Analysis Calculated for $\text{C}_{15}\text{H}_{17}\text{ClN}_4 \cdot \text{HCl}$: C, 55.40; H, 5.58; N, 17.23. Found: C, 55.14; H, 5.61; N, 17.44.

EXAMPLE 7.

1,3 - Dimethyl - 4 - [3 - (N' - methylpiperazino)propylamino] - 1H - pyrazolo[3,4b]quinoline dihydrochloride

A mixture of 4-(3-chloropropylamino)-1,3-dimethyl-1H-pyrazolo[3,4b]quinoline hydrochloride (4.63 g., 0.02 mole), N-(η -aminopropyl)-N'-methylpiperazine (3.15 g., 0.02 mole), and potassium carbonate (2.76 g., 0.02 mole) in DMF (60 ml.) was stirred at 130°C for 18 hours. The solvent was removed at 5 mm, and the residue was dissolved in chloroform. The solution was washed with water, dried and evaporated to leave 5.24 g. (75%). Treatment with two equivalents of hydrochloric acid yielded 1,3-dimethyl-4-[3-(N'-methylpiperazino)propylamino]-1H-pyrazolo[3,4b]quinoline dihydrochloride; mp $266\text{--}270^\circ\text{C}$. (dec.) after recrystallization (ethanol).

Analysis Calculated for $\text{C}_{20}\text{H}_{28}\text{N}_6 \cdot 2\text{HCl}$: C, 56.47; H, 7.11; N, 19.76. Found: C, 55.90; H, 6.80; N, 19.91.

13

6

1,488,692

6

EXAMPLE 8.

1,3 - Dimethyl - 4 - (3 - dimethylaminopropylamino) - 6 - nitro - 1H - pyrazolo[3,4b]quinoline

A mixture of 70% nitric acid (1.2 ml.) and 95% sulfuric acid (13.6 ml.) was added dropwise over 30 minutes to a solution at 5—10°C. of 3-dimethyl-4-(3-dimethylaminopropylamino)-1H-pyrazolo[3,4b]quinoline (0.017 mole) in nitromethane (30 ml.). After the addition, the mixture was stirred at 10—20°C. for 2 hours, and then was poured with cold water and neutralized with ammonium hydroxide. The product was isolated by extraction into chloroform and worked up in the usual manner; yield, 4.61 g. (82%), mp 189—192°C.; dihydrochloride salt, mp 262—264°C. (dec.).

Analysis Calculated for $C_{17}H_{22}N_6O_2 \cdot 2HCl$: C, 49.17; H, 5.83; N, 20.23. Found: C, 48.54; H, 6.02; N, 20.08.

EXAMPLE 9.

6 - Amino - 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 1H - pyrazolo[3,4b]quinoline Dihydrochloride

The nitro compound of Example 8 (4.00 g., 0.012 mole) suspended in ethanol (100 ml.) containing 5% Pd/C (0.4 g.) was shaken under hydrogen at an initial pressure of 50 psi for 2.5 hours. The catalyst was removed by filtration and the solvent was evaporated to leave the 6-amino-1,3-dimethyl-4-(3-dimethylaminopropylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride. It is necessary to store the compound under nitrogen because it rapidly darkens upon exposure to air. The compound was converted to the dihydrochloride salt in the usual manner and recrystallized (ethanol); mp 305°C. (dec.).

Analysis Calculated for $C_{17}H_{24}N_6 \cdot 2HCl$: C, 52.99; H, 6.80; N, 21.81. Found: C, 51.19; H, 7.21; N, 21.07.

EXAMPLE 10.

6 - Acetamido - 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 1H - pyrazolo[3,4b]quinoline

The amine of Example 9 (1.85 g., 0.0059 mole) in pyridine (30 ml.) was treated with acetic anhydride (0.61 g., 0.0059 mole) and the solution was stirred at 28°C. for 16 hours. The solution was poured onto ice-water, treated with 4N aqueous NaOH and extracted with chloroform. Evaporation of the dried organic phase yielded 6-acetamido-1,3-dimethyl-4-(3-dimethylaminopropylamino)-1H-pyrazolo[3,4b]quinoline; recrystallization from water gave mp 64—76°C. (hydrated).

Analysis Calculated for $C_{19}H_{26}N_6O$: C, 64.38; H, 7.39; N, 23.71. Found: (corrected for 3.76% water of hydration): C, 64.52; H, 7.12; N, 24.08.

EXAMPLE 11.

1,3 - Dimethyl - 4 - (3 - dimethylaminopropylamino) - 6 - ethylamino - 1H - pyrazolo[3,4b]quinoline

The acetamido compound of Example 10 (1.34 g., 0.0038 mole) in tetrahydrofuran (THF) (10 ml.) was added over a 30 minute period to 8.86 ml. of 1 molar borane in THF at 5—10°C. After the addition, the solution was refluxed for 1.5 hours, then cooled and treated with 4N hydrochloric acid (6 ml.). The THF was evaporated and the aqueous phase was neutralized with 4N sodium hydroxide. Extraction with chloroform and workup in the usual manner yielded 1,3-dimethyl-4-(3-dimethylaminopropylamino)-6-ethylamino-1H-pyrazolo[3,4b]quinoline; treatment with three equivalents of hydrochloric acid and subsequent recrystallizations from ethanol gave an equimolar mixture of di and trihydrochloride salts; mp 210—214°C. (dec.).

Analysis Calculated for $C_{19}H_{28}N_6 \cdot 2.5HCl$: C, 52.87; H, 7.12; N, 19.47; Cl, 20.53. Found: C, 53.23; H, 6.63; N, 19.80; Cl, 20.86.

EXAMPLE 12.

4 - (3 - Dimethylaminopropylamino)-1,3,6,7 - tetramethyl - 1H - pyrazolo[3,4b]quinoline dihydrochloride

N-(1,3-dimethyl-5-pyrazolyl)-4,5-dimethylantranilic acid (2.85 g., 0.011 mole) and phosphorous oxychloride (60 ml.) was stirred at reflux for 1.5 hours. The POCl₃ was then evaporated and the residue cooled, adding excess 3-dimethylaminopropylamine (about 60 ml.). The reaction mixture then was refluxed for 16 hours. The reaction then was cooled and evaporated.

14

The residue was dissolved in chloroform and the resultant solution was washed in succession with aqueous potassium carbonate, water and brine, dried with Na_2SO_4 and evaporated to yield 3.34 g. of a yellow solid (94% yield). Dissolution in 1-propanol and heating with 2 equivalents of aqueous 1N hydrochloric acid yield, after filtering and cooling to 4°C . there was recovered 4 - (3 - Dimethylaminopropylamino) - 1,3,6,7 - tetramethyl - 1H - pyrazolo[3,4b]quinoline dihydrochloride, white crystals, mp greater than 300°C .

Analysis Calculated for $\text{C}_{19}\text{H}_{27}\text{N}_5 \cdot 2\text{HCl}$: C, 57.28; H, 7.34; N, 17.58. Found: C, 56.88; H, 7.12; N, 17.19.

EXAMPLE 13.

1,3 - Dimethyl - 4 - (3 - dimethylaminopropylamino) - 6 - methoxy - 1H - pyrazolo[3,4b]quinoline dihydrochloride

4-chloro-1,3-dimethyl-6-methoxy-1H-pyrazolo[3,4b]quinoline 0.825g.(0.00316 mol) prepared as above from N-(1,3-dimethyl-pyrazolyl)-5-methoxyanthranilic acid, was mixed with about 10 ml. of 3-dimethylaminopropylamine and refluxed for 16 hours. The product was cooled and extracted as above, isolated and treated in 1-propanol with 2 equivalents in aqueous 1N HCl and then evaporated. The solid was dissolved in hot ethanol then cooled to 4° and stored until needle like crystals formed. Filtered and the crystals were repeatedly washed with cold ethanol. Crystals were dried under vacuum. M.P. $281-282^\circ\text{C}$. (dec.).

Analysis Calculated for $\text{C}_{18}\text{H}_{23}\text{N}_5\text{O} \cdot 2\text{HCl}$: C, 54.00; H, 6.80; N, 17.49. Found: C, 53.87; H, 6.49; N, 17.51.

EXAMPLE 14.

1,3 - Dimethyl - 4 - (3 - dimethylaminopropylamino) - 7 - ethyl - 1H - pyrazolo[3,4b]quinoline dihydrochloride

A mixture of N-(1,3-dimethyl-5-pyrazolyl)-4-ethylanthranilic acid (5.00 g., .0193 mol) and phosphorus oxychloride (50 ml.) was stirred at reflux for 2 hours. Excess POCl_3 was then removed at reduced pressure and the residue heated with 3-dimethylaminopropylamine (60 ml) at 130°C . for 16 hours.

The excess amine was then removed at reduced pressure and the oily residue taken up in chloroform, washed with aqueous sodium carbonate, water and brine, dried over Na_2SO_4 and the chloroform evaporated to yield 6.98 g. of a yellow brown oil.

The dihydrochloride salt was prepared, as above, using 4.0N HCl. The crude solid salt was washed with acetone and recrystallized from N-propanol, then isopropanol to yield 5.25 g. of a white solid, 1,3-dimethyl-4-(1,3-dimethylaminopropylamino) - 7 - ethyl - 1H - pyrazolo[3,4b]quinoline dihydrochloride, M.P. $248-251^\circ\text{C}$. (dec.).

Analysis calculated for $\text{C}_{19}\text{H}_{27}\text{N}_5 \cdot 2\text{HCl}$: C, 57.29; H, 7.34; N, 17.58. Found: C, 57.20; H, 7.61; N, 17.62.

EXAMPLE 15.

1,3 - Dimethyl - 4 - (3 - dimethylaminopropylamino) - 6,7 - dimethoxy - 1H - pyrazolo[3,4b]quinoline dihydrochloride

A mixture of N-(1,3-dimethyl-5-pyrazolyl)-4,5-dimethoxyanthranilic acid (7.0 g., .0241 mol) and phosphorus oxychloride (100 ml.) was stirred at reflux for 3 hours, cooled and the excess POCl_3 removed under reduced pressure. The resultant solid was heated with 3-dimethylaminopropylamine (100 ml.) at 174°C . for 18 hours.

The cooled reaction mixture was partitioned between a large volume of aqueous sodium carbonate and chloroform. The organic layer then was washed with water and brine, dried over Na_2SO_4 and evaporated to yield 5.0 g. of semicrystalline material which was rubbed under cold ether and filtered. The filtrate was concentrated to remove solvent yielding 3.35 g. of a viscous oil which was placed on 75 g. of alumina on a column and eluted with 500 ml. 95/5, ether/ethanol. The eluant was concentrated to dryness yielding 2.10 g. of an oil, which partially crystallized on standing. This material was rubbed under a minimum amount of cold ether and filtered to yield 753 mg. of sticky solid. The dihydrochloride salt was prepared as previously described. M.P. $259-261^\circ\text{C}$. (dec.).

Analysis Calculated for $\text{C}_{19}\text{H}_{27}\text{N}_5\text{O}_2 \cdot 2\text{HCl}$: C, 53.03; H, 6.79; N, 16.27. Found: C, 53.55; H, 6.66; N, 15.90.

EXAMPLE 16.

1,3 - Dimethyl - 4 - (3 - dimethylaminopropylamino) - 7 - chloro - 1H - pyrazolo[3,4b]quinoline dihydrochloride

In the manner of the previous Examples N-(1,3-dimethyl-5-pyrazolyl)-4-chloroanthranilic acid was reacted with POCl₃ followed by 3-dimethylaminopropylamine. The product was dissolved in chloroform, washed and isolated as previously described. The dihydrochloride salt was formed, washed with acetone and recrystallized from hot aqueous ethanol to yield 4-(3-dimethylaminopropylamino)-1,3-dimethyl-7-chloro-1H-pyrazolo[3,4b]quinoline dihydrochloride.

Analysis Calculated for C₁₇H₂₂ClN₅·2HCl: C, 50.57; H, 5.96; N, 17.30. Found: C, 50.70; H, 6.17; N, 17.71.

EXAMPLE 17.

1,3 - Dimethyl - 4 - (3 - piperazinopropylamino) - 1H - pyrazolo[3,4b]quinoline trihydrochloride

4-(3-chloropropylamino)-1,3-dimethyl-1H-pyrazolo[3,4b]quinoline (3.00 g., 0.00923 mol) was reacted with excess piperazine under nitrogen at 148°C. for 16 hours. The cooled pasty reaction product was partitioned between water and chloroform. The organic phase was washed with water and brine, dried and evaporated. The product was washed with toluene, filtered and the filtrate concentrated to yield 1.52 g. of yellow-brown gum. A trihydrochloride was prepared as previously described. The crude salt was washed with acetone and filtered to yield 1.18 g. of yellow solid which was recrystallized from aqueous ethanol to yield 850 mg., 1,3-dimethyl-4-(3-piperazinopropylamino)-1H-pyrazolo[3,4b]quinoline trihydrochloride, M.P. 282–286°C. (dec.).

Analysis Calculated for C₁₉H₂₈N₆·3HCl: C, 50.97; H, 6.53; N, 18.77. Found: C, 51.25; H, 6.03; N, 19.00.

EXAMPLE 18.

1,3 - Dimethyl - 4 - (3 - Isopropylaminopropylamino) - 1H - pyrazolo[3,4b]quinoline dihydrochloride

4-(3-chloropropylamino)-1,3-dimethyl-1H-pyrazolo[3,4b]quinoline (3.50 g., 0.01075 mol) was reacted with isopropylamine (40 ml.) in a pressure vessel at 100°C. for 16 hours. The cooled reaction product was dissolved in chloroform and washed with aqueous sodium carbonate; water and brine, dried and evaporated. The dihydrochloride salt was prepared from the free base and aqueous 4N HCl. The crude salt was washed with acetone and recrystallized from aqueous ethanol to recover 1.75 g. 1,3-dimethyl-4-(3-isopropylaminopropylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride; M.P. greater than 300°C.

Analysis Calculated for C₁₈H₂₅N₅·2HCl: C, 56.26; H, 7.08; N, 18.22. Found: C, 56.25; H, 6.95; N, 18.32.

EXAMPLE 19.

1,3 - Dimethyl - 4 - (3 - *tert* - butylaminopropylamino) - 1H - pyrazolo[3,4b]quinoline dihydrochloride

In the manner of Example 18, replacing isopropylamine with *tert*-butylamine, there was prepared 4-(3-*tert*-butylaminopropylamino)-1,3-dimethyl-1H-pyrazolo[3,4b]quinoline dihydrochloride.

Analysis Calculated for C₁₉H₂₇N₅·2HCl: C, 57.29; H, 7.34; N, 17.58. Found: C, 57.11; H, 7.31; N, 18.04.

EXAMPLE 20.

4 - (3 - Dimethylaminopropylamino) - 1,3,6 - trimethyl - 1H - pyrazolo[3,4b]quinoline dihydrochloride

A mixture of N(1,3-dimethyl-5-pyrazolyl)-5-methylantranilic acid (3.70 g., 0.0151 mol) and phosphorus oxychloride (65 ml.) was stirred at reflux for 3 hours. After removal of excess POCl₃, there was added an excess of 3-dimethylaminopropylamine and the mixture refluxed for 16 hours. The excess amine was then removed and the product extracted with chloroform, washed and isolated, as described above, to yield 4.59 g. of a yellow solid. The product dissolved in 1-propanol was treated with two equivalents of 1N aqueous HCl to form the dihydrochloride which was isolated by evaporation. The product was recrystallized from ethanol to yield 4.06 g. of a white solid 4-(3-dimethylaminopropylamino)-1,3,6-trimethyl-1H-pyrazolo[3,4b]quinoline dihydrochloride; M.P. 274°C. (dec.).

Analysis Calculated for $C_{18}H_{25}N_3 \cdot 2HCl$: C, 56.25; H, 7.08; N, 18.22. Found: C, 57.75; H, 6.62; N, 18.48.

In the manner of the general reaction schemes set forth and the preceding examples there were prepared the following compounds:

EXAMPLE 21.

1,3 - Dimethyl - 4 - (3 - dimethylaminopropylamino) - 5 - methoxy - 1H - pyrazolo[3,4b]quinoline dihydrochloride

Recrystallized from aqueous ethanol, M.P. 278°C. (dec.).

Analysis Calculated for $C_{18}H_{25}N_3O \cdot 2HCl$:

C, 54.00; H, 6.80; N, 17.49. Found:

C, 54.17; H, 6.72; N, 17.43.

EXAMPLE 22.

1,3 - Dimethyl - 4 - (2 - dimethylaminoethylamino) - 1H - pyrazolo[3,4b]quinoline dihydrochloride

Recrystallized from aqueous ethanol, M.P. greater than 300°C.

Analysis Calculated for $C_{16}H_{21}N_3 \cdot 2HCl$:

C, 53.94; H, 6.51; N, 19.66. Found:

C, 54.10; H, 6.38; N, 19.98.

EXAMPLE 23.

1,3 - Dimethyl - 4 - (5 - dimethylaminopentylamino) - 1H - pyrazolo[3,4b]quinoline dihydrochloride

Recrystallized from ethanol, M.P. 268—271°C. (dec.).

Analysis Calculated for $C_{19}H_{27}N_3 \cdot 2HCl$:

C, 57.28; H, 7.38; N, 17.58. Found:

C, 57.09; H, 7.05; N, 17.68.

EXAMPLE 24.

1,3 - Dimethyl - 4 - (6 - dimethylaminoethylamino) - 1H - pyrazolo[3,4b]quinoline dihydrochloride

Recrystallized from ethanol, M.P. 215—219°C. (dec.).

Analysis Calculated for $C_{20}H_{29}N_3 \cdot 2HCl$:

C, 58.25; H, 7.58; N, 16.99. Found:

C, 58.32; H, 7.74; N, 16.83.

EXAMPLE 25.

1,3 - Dimethyl - 4 - (3 - methylaminopropylamino) - 1H - pyrazolo[3,4b]quinoline dihydrochloride

Recrystallized from ethanol, M.P. 307—309°C. (dec.).

Analysis Calculated for $C_{17}H_{23}N_3 \cdot 2HCl$:

C, 53.94; H, 6.51; N, 19.66. Found:

C, 54.20; H, 6.58; N, 19.70.

EXAMPLE 26.

1,3 - Dimethyl - 4 - (3 - aminopropylamino) - 1H - pyrazolo[3,4b]quinoline dihydrochloride

Recrystallized from ethanol, M.P. 311—314°C. (dec.).

Analysis Calculated for $C_{15}H_{19}N_3 \cdot 2HCl$:

C, 52.64; H, 6.19; N, 20.46. Found:

C, 52.45; H, 6.33; N, 20.60.

EXAMPLE 27.

1,3 - Dimethyl - 4 - (3 - dimethylaminopropylamino) - 8 - methoxy - 1H - pyrazolo[3,4b]quinoline dihydrochloride

Recrystallized from ethanol, M.P. 261.5—263°C. (dec.).

Analysis Calculated for $C_{18}H_{25}N_3O \cdot 2HCl$:

C, 54.00; H, 6.80; N, 17.49. Found:

C, 54.26; H, 7.03; N, 17.90.

EXAMPLE 28.

1,3 - Dimethyl - 4 - (3 - dimethylaminopropylamino) - 7 - methoxy - 1H - pyrazolo[3,4b]quinoline dihydrochloride

Recrystallized from ethanol, M.P. 261—263°C.

Analysis Calculated for $C_{18}H_{25}N_3O \cdot 2HCl$:

C, 54.00; H, 6.80; N, 17.49. Found:

C, 53.85; H, 7.19; N, 17.63.

17

10

1,488,692

10

EXAMPLE 29.

1,3 - Dimethyl - 4 - (3 - dimethylaminopropylamino) - 5,7 - dimethoxy - 1H - pyrazolo[3,4b]quinoline dihydrochloride

Recrystallized from ethanol, M.P. 285°C. (dec.).

Analysis Calculated for $C_{19}H_{27}N_5O_2 \cdot 2HCl$:

C, 53.03; H, 6.79; N, 16.27. Found:

C, 52.96; H, 6.93; N, 16.44.

The compounds of this invention demonstrate antiviral activity making them useful as antiviral agents in mammals. The compounds of the instant invention have shown interferon-eliciting activity when administered to mice either p.o. or i.p.

The compounds of Examples 3 and 20 have been shown effective against tail lesions induced by vaccinia virus in mice (50 mg/kg. orally) following the procedure of Boyle et al, "Antimicrobial Agents and Chemotherapy" (1966): 536—539 (1967). Specifically, the compound was administered to mice at any time from 6—24 hours prior to challenge with virus. Vaccinia virus, IHD strain, was introduced into the animals via the tail vein at a dose sufficient to produce 20 to 30 tail lesions per mouse. Lesions were enumerated after 7 days. A reduction in the lesion score of greater than 50% was considered significant.

The interferon-eliciting tests summarized in the following table were performed as follows: various concentrations of the compounds, as indicated were administered to 15 gram female CD-1 mice (Charles River Breeding Laboratories) by oral or intraperitoneal route. Approximately 16—18 hours later, the mice were exsanguinated, serum collected and tested on mouse L cells for ability to prevent subsequent infection by vesicular stomatitis virus or mouse picornavirus GD-7. See Siminoff et al, "Antimicrobial Agents and Chemotherapy" 3:742—743 (1973) and Baron et al, "Science" 141:1061—1063 (1963). In the following table, a "+" indicates activity, a "±" low activity and a "-" lack of significant activity. "T" indicates toxicity.

18

Interferon Activity

	p.o.			i.p.		
	(Mg/Kg)			(Mg/Kg)		
	400	100		300	100	
4-(3-dimethylaminopropylamino)-1,3,7-trimethyl-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 3)	+	+		T	+	
4-(3-dimethylaminopropylamino)-1,3,6-trimethyl-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 20)	+	+		T	+	
4-(3-dimethylaminopropylamino)-1,3,6,7-tetramethyl-1H-pyrazolo[3,4b]-quinoline dihydrochloride (Ex. 12)				+	+	
1,3-dimethyl-4-(3-dimethylaminopropylamino)-6,7-dimethoxy-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 15)				+	+	
1,3-dimethyl-4-(3-dimethylaminopropylamino)-5,7-dimethoxy-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 29)				+	+	
1,3-dimethyl-4-(3-dimethylaminopropylamino)-6-methoxy-1H-pyrazolo[3,4b]-quinoline dihydrochloride (Ex. 13)	+	±		+	±	
1,3-dimethyl-4-(3-dimethylaminopropylamino)-5-methoxy-1H-pyrazolo[3,4b]-quinoline dihydrochloride (Ex. 21)	+	+		+	+	
1,3-dimethyl-4-(3-dimethylaminopropylamino)-7-methoxy-1H-pyrazolo[3,4b]-quinoline dihydrochloride (Ex. 28)	±	+		+	+	
1,3-dimethyl-4-(3-dimethylaminopropylamino)-8-methoxy-1H-pyrazolo[3,4b]-quinoline dihydrochloride (Ex. 27)		+		+	+	
1,3-dimethyl-4-(3-dimethylaminopropylamino)-7-chloro-1H-pyrazolo[3,4b]-quinoline dihydrochloride (Ex. 16)				+	+	
1,3-dimethyl-4-(3-dimethylaminopropylamino)-6-ethylamino-1H-pyrazolo[3,4b]quinoline-trihydrochloride (Ex. 11)				+	+	

19

12

1,488,692

12

(Continued)

	Interferon Activity		
	p.o.	(Mg/Kg)	i.p. (Mg/Kg)
	400	100	300 100
1,3-dimethyl-4-(2-dimethylaminoethylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 22)	±	-	
1,3-dimethyl-4-(4-dimethylaminobutylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 4)	+		
1,3-dimethyl-4-(5-dimethylaminopentylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 23)	+	+	+
1,3-dimethyl-4-(6-dimethylaminohexylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 24)	+		
1,3-dimethyl-4-(3-methylaminopropylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 25)	+	-	+
1,3-dimethyl-4-(3-N-methylpiperazinylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 7)	+	+	+
1,3-dimethyl-4-(3-aminopropylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 26)	+	-	+
1,3-dimethyl-4-(3-piperazinopropylamino)-1H-pyrazolo[3,4b]quinoline trihydrochloride (Ex. 17)			+
1,3-dimethyl-4-(3-isopropylaminopropylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 18)			-
1,3-dimethyl-4-(3-t-butylaminopropylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 19)			+
1,3-dimethyl-4-(3-dimethylaminopropylamino)-7-ethyl-1H-pyrazolo[3,4b]quinoline dihydrochloride (Ex. 14)			T

(Continued)


	Interferon Activity			
	p.o.	(Mg/Kg)	i.p.	(Mg/Kg)
	400	100	300	100
1,3-dimethyl-4-(3-dimethylaminopropylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride	+	-	+	±
4-(3-dimethylaminopropylamino)-1,3,7,8-tetramethyl-1H-pyrazolo[3,4b]-quinoline dihydrochloride	+	±		
4-(3-dimethylaminopropylamino)-1,3,6,8-tetramethyl-1H-pyrazolo[3,4b]-quinoline dihydrochloride	+	-		

The compounds of the instant invention are capable of eliciting interferon synthesis and release, thereby making them effective as prophylactic and therapeutic agents in the prevention and/or treatment of viral infections in mammals, including man.

The compounds are administered in man at a dosage in the range of 50-2000 mg three to four times a day, dependent upon the weight of the subject and the route of administration.

WHAT WE CLAIM IS:—

1. A compound corresponding to the formula



or a pharmaceutically acceptable salt thereof, where E is hydrogen, lower alkoxy, lower alkylthio, hydroxyl, thio, trifluoromethyl, lower dialkylaminoalkoxy, amino, lower alkylamino, or lower dialkylamino,



* C L N S *

20

(Continued)


	Interferon Activity		
	p.o. (Mg/Kg)	i.p. (Mg/Kg)	
	400	100	300 100
1,3-dimethyl-4-(3-dimethylaminopropylamino)-1H-pyrazolo[3,4b]quinoline dihydrochloride	+	-	+
4-(3-dimethylaminopropylamino)-1,3,7,8-tetramethyl-1H-pyrazolo[3,4b]-quinoline dihydrochloride	+	±	
4-(3-dimethylaminopropylamino)-1,3,6,8-tetramethyl-1H-pyrazolo[3,4b]-quinoline dihydrochloride	+	-	

The compounds of the instant invention are capable of eliciting interferon synthesis and release, thereby making them effective as prophylactic and therapeutic agents in the prevention and/or treatment of viral infections in mammals, including man.

The compounds are administered in man at a dosage in the range of 50—2000 mg three to four times a day, dependent upon the weight of the subject and the route of administration.

WHAT WE CLAIM IS:—

1. A compound corresponding to the formula



or a pharmaceutically acceptable salt thereof, where E is hydrogen, lower alkoxyl, lower alkylthio, hydroxyl, thio, trifluoromethyl, lower dialkylaminoalkoxy, amino, lower alkylamino, or lower dialkylamino,



1,488,692

14

where F is hydrogen, lower alkyl, lower alkoxy, hydroxyl, lower alkylthio, thio, trifluoromethyl, lower dialkylaminoalkoxy, amino, lower alkylamino, or lower dialkylamino,

where G is hydrogen, lower alkyl, lower alkoxy, hydroxyl, lower alkylthio, thio, trifluoromethyl, lower dialkylaminoalkoxy, amino, lower alkylamino, or lower dialkylamino,


where J is hydrogen, lower alkyl, lower alkoxy, hydroxyl, lower alkylthio, thio, trifluoromethyl, lower dialkylaminoalkoxy, amino, lower alkylamino, or lower dialkylamino,

where n is an integer from 2 to 12,

where Y is amino, lower alkylamino, lower dialkylamino, or heteroamino wherein the heteroamino group is a 5 or 6 membered saturated substituted or unsubstituted ring;

and where at least one of E, F, G and J is other than hydrogen.

2. A compound, as in claim 1, corresponding to the formula



or a pharmaceutically acceptable salt thereof,

where E is hydrogen or lower alkoxy,


where F is hydrogen, lower alkyl, lower alkoxy or lower alkylamino,

where G is hydrogen, lower alkoxy, or lower alkyl,

and where J is hydrogen, or lower alkoxy,

where one to two of E, F, G and J are other than hydrogen;


where n is an integer from 2 to 6 inclusive and where Y is amino dimethylamino, diethylamino, dipropylamino, methylamino, ethylamino, propylamino, tertiary-butylamino, or a heteroradical from the group



3. A compound, as in claim 1, which is 4 - (3 - dimethylaminopropylamino) - 1,3,6 - trimethyl - 1H - pyrazolo[3,4b]quinoline; 4 - (3 - dimethylaminopropylamino) - 1,3,7 - trimethyl - 1H - pyrazolo[3,4b]quinoline; 4 - (3 - dimethylaminopropylamino) - 1,3,6,7 - tetramethyl - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 5 - methoxy - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 6 - methoxy - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 7 - methoxy - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 8 - methoxy - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 6,7 - dimethoxy - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 5,7 - dimethoxy - 1H - pyrazolo[3,4b]quinoline; or a pharmaceutically acceptable salt thereof.

4. A compound, as in claim 1, 2, or 3, which is a dihydrochloride salt.

5. A method of inducing interferon activity in a non-human mammal, prophylactically or therapeutically, which comprises administering an interferon eliciting amount of a compound corresponding to the formula



or a pharmaceutically acceptable salt thereof,

where E is hydrogen, halogen, lower alkoxy, lower alkylthio, thio, trifluoromethyl, lower dialkylaminoalkoxy, amino, lower alkylamino or lower dialkylamino,



22

15

1,488,692

15

where F is hydrogen, lower alkyl, lower alkoxy, lower alkylthio, hydroxyl, thio, trifluoromethyl, lower dialkylaminoalkoxy, amino, lower alkylamino or lower dialkylamino,


where G is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkylthio, hydroxyl, thio, trifluoromethyl, lower dialkylaminoalkoxy, amino, lower alkylamino or lower dialkyl amino,

where J is hydrogen, halogen, lower alkoxy, lower alkylthio, hydroxyl, thio, trifluoromethyl, lower dialkylaminoalkoxy, amino, lower alkylamino or lower dialkylamino,

where n is an integer from 2 to 12 inclusive,

and Y is amino, lower alkylamino, lower dialkylamino, or a heteroamino group wherein the heteroamino group is a 5 or 6 membered saturated substituted or unsubstituted ring; and where when n is 3 and 7 is lower dialkylamino at least one of E, F, G and J is other than hydrogen; and thereby preventing or curing a virus infection.

6. A method as in claim 5, wherein the compound is a compound corresponding to the formula



or a pharmaceutically acceptable salt thereof,

where E is hydrogen or lower alkoxy,


where F is hydrogen, lower alkyl, lower alkoxy or lower alkylamino,

where G is hydrogen, lower alkoxy, lower alkyl or halogen,

and where J is hydrogen, or lower alkoxy,

where one to two of E, F, G and J are other than hydrogen,

where n is an integer from 2 to 6 inclusive, and where Y is amino, dimethylamino, diethylamino, dipropylamino, methylamino, ethylamino, propylamino, tertiary-butylamino, or a heteroradical from the group of



7. A method, as in claim 5 or 6, wherein the compound is 4 - (3 - dimethylaminopropylamino) - 1,3,6 - trimethyl - 1H - pyrazolo[3,4b]quinoline; 4 - (3 - dimethylaminopropylamino) - 1,3,7 - trimethyl - 1H - pyrazolo[3,4b]quinoline; 4 - (3 - dimethylaminopropylamino) - 1,3,6,7 - tetramethyl - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 5 - methoxy - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 6 - methoxy - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 7 - methoxy - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 8 - methoxy - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 6,7 - dimethoxy - 1H - pyrazolo[3,4b]quinoline; or 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) 5,7 - dimethoxy - 1H - pyrazolo[3,4b]quinoline; or a pharmaceutically acceptable salt thereof.

8. A method as in claim 5, 6 or 7, wherein the compound is a dihydrochloride salt.

9. A method or inhibiting a virus selected from the group consisting of Vaccinia virus, vesicular stomatitis virus or picornavirus which comprises administering to a non-human recipient a virus inhibiting amount of 4 - (3 - dimethylaminopropylamino) - 1,3,6 - trimethyl - 1H - pyrazolo[3,4b]quinoline; 4 - (3 - dimethylaminopropylamino) - 1,3,7 - trimethyl - 1H - pyrazolo[3,4b]quinoline; 4 - (3 - dimethylaminopropylamino) - 1,3,6,7 - tetramethyl - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 5 - methoxy - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 6 - methoxy - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 7 - methoxy - 1H - pyrazolo[3,4b]quinoline;

23




1,488,692

16

5

1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 8 - methoxy - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 1H - pyrazolo[3,4b]quinoline; 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 6,7 - dimethoxy - 1H - pyrazolo[3,4b]quinoline; or 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 5,7 - dimethoxy - 1H - pyrazolo[3,4b]quinoline; or a pharmaceutically acceptable salt thereof.

10. A process for preparing the compound of claim 1, which comprises treating a 4-chloro-1,3-dimethyl-1H-pyrazolo[3,4b]



10

in which E, F, G and J have the meanings given above, with a compound having the formula



in which Y and n have the meanings given in claim 1, in a molar ratio of at least 1 mole of the compound

15




per mol of the compound of Formula (IV), with or without the presence of a nonreactive solvent, with or without the adding of heat.

11. A process for preparing the compound of claim 1, which comprises treating the compound of Formula (IV) with a compound having the formula

20



in which n has the meaning given in claim 1, then isolating the resulting product and treating it with thionyl chloride to obtain the chloro derivative of the formula



25

in which E, F, G and J have the meanings given above, and then treating the resulting compound with the appropriate amine for obtaining the compound of claim 1.

30

12. A compound which is:
- 1,3 - dimethyl - 4 - [3 - N' - methylpiperazino)propylamino] - 1H - pyrazolo[3,4b]quinoline or its dihydrochloride;
 - 1,3 - dimethyl - 4 - (3 - piperazinopropylamino) - 1H - pyrazolo[3,4b]quinoline or its trihydrochloride;
 - 1,3 - dimethyl - 4 - (3 - isopropylaminopropylamino) - 1H - pyrazolo[3,4b]quinoline or its dihydrochloride;
 - 1,3 - dimethyl - 4 - (3 - tert - butylaminopropylamino) - 1H - pyrazolo[3,4b]quinoline or its dihydrochloride;
 - 1,3 - dimethyl - 4 - (2 - dimethylaminoethylamino) - 1H - pyrazolo[3,4b]quinoline or its dihydrochloride;
 - 1,3 - dimethyl - 4 - (5 - dimethylaminopentylamino) - 1H - pyrazolo[3,4b]quinoline or its dihydrochloride;
 - 1,3 - dimethyl - 4 - (6 - dimethylaminohexylamino) - 1H - pyrazolo[3,4b]quinoline or its dihydrochloride;
 - 1,3 - dimethyl - 4 - (3 - methylaminopropylamino) - 1H - pyrazolo[3,4b]quinoline or its dihydrochloride; or
 - 1,3 - dimethyl - 4 - (3 - aminopropylamino) - 1H - pyrazolo[3,4b]quinoline or its dihydrochloride.

45

5

10

15

20

25

30

35

40

45



(24)

17

1,488,692

17

13. A process for preparing a compound in accordance with claim 1 substantially as hereinbefore described.

5

14. A process for preparing a compound in accordance with claim 1 substantially as hereinbefore described with reference to any one of the Examples 3, 4, 9 to 16, 20, 21 and 27 to 29.

5

15. A process for preparing a compound in accordance with claim 12 substantially as hereinbefore described with reference to any one of Examples 7, 17 to 19 and 22 to 26.

10

16. A compound in accordance with claim 1 when prepared by a process according to any one of claims 10, 11, 13 or 14.

10

17. A compound in accordance with claim 1 as hereinbefore specifically mentioned.

15

18. 1,3 - dimethyl - 4 - (3 - dimethylaminopropylamino) - 5,7 - dimethoxy - 1H - pyrazolo[3,4b]quinoline, or a pharmaceutically acceptable salt thereof.

19. A compound in accordance with any one of claims to 4, or 16 to 18 in unit dosage form.

15

20. A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 4, 12 or 16 to 19 in admixture with a pharmacologically-acceptable carrier.

For the Applicants,
CARPMAELS & RANSFORD,
Chartered Patent Agents,
43 Bloomsbury Square,
London, WC1A 2RA.

Printed for Her Majesty's Stationery Office by the Courier Press, Leamington Spa, 1977.
Published by the Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from
which copies may be obtained.

ERRATUM

SPECIFICATION No. 1,488,692

Page 1, Heading, (54), for [3,4,6] read
[3,4,b]

THE PATENT OFFICE
27th March, 1978

(7)